CJC-IPAMORELIN Blend

The CJC-1295/Ipamorelin blend combines two research peptides that act on the growth hormone axis through distinct mechanisms. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist. Their combination is studied in research for synergistic effects on GH secretion dynamics.

The CJC-1295/Ipamorelin blend combines a GHRH analogue (CJC-1295) with a selective ghrelin receptor agonist (Ipamorelin) for research into dual-pathway growth hormone axis modulation. Supplied as a lyophilized peptide blend for laboratory investigation.

CJC-1295 was developed as a long-acting GHRH analogue with enhanced stability through amino acid substitutions. Ipamorelin was identified through peptide library screening as a highly selective ghrelin receptor agonist with minimal effects on ACTH or cortisol in preclinical studies. The combination approach emerged from research into dual-axis GH pathway modulation.

Preclinical studies of CJC-1295 have demonstrated sustained elevation of GH and IGF-1 levels in animal models through GHRH receptor agonism. Ipamorelin research has shown selective GH release without significant cortisol or prolactin elevation. Combination studies aim to characterize amplified GH pulsatility through simultaneous stimulation of both GHRH and GHSR pathways.